Drug intelligence / Profile preview

MVP-SQ9

Development stage: Preclinical
Lead developer: Multiverse Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

MVP-SQ9 is a preclinical-stage biologic therapeutic candidate being developed by Multiverse Pharma. The asset is engineered using the company's proprietary Fc heterodimerization technology, a protein engineering platform designed to facilitate the production of multi-specific therapeutics, such as bispecific antibodies or heterodimeric fusion proteins, by ensuring the correct assembly of distinct polypeptide chains. As of early 2026, Multiverse Pharma has not publicly disclosed the specific molecular targets or the primary therapeutic indications for MVP-SQ9, though the platform is generally applied to oncology and inflammatory diseases.

Other names: MVP-SQ9MVP-SQ-9MVP-SQ 9

Beyond the preview

Go deeper on MVP-SQ9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP-SQ9.

Explore the full profile